Natco Pharma Limited has informed the Exchange regarding a press release dated August 20, 2025, titled "NATCO launches Bosentan Tablets for Oral Suspension (generic of Tracleer®) in the United States with 180-day exclusivity".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has launched Bosentan tablets for oral suspension (32mg) in the United States, a generic version of Actelion's Tracleer® used to treat pulmonary arterial hypertension in pediatric patients aged 3 and above. The company holds first-to-file status, granting it 180 days of generic drug exclusivity in the US market. Lupin Limited will serve as the marketing partner for the product. The product had estimated US sales of USD 10 million for the 12 months ending June 2025, indicating a niche but meaningful opportunity.
Positive near-term for the stock — 180-day exclusivity means Natco and partner Lupin will be the only generic supplier in the US for six months, allowing them to capture the full market value of a USD 10 million product at likely favorable pricing. While the absolute size is modest, it strengthens Natco's US pipeline and exclusivity track record.